Wolff-Parkinson-White syndrome medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 105: Line 105:
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=left |❑ Repeat the dosage if the [[tachycardia]] continues <br>
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=left |❑ Repeat the dosage if the [[tachycardia]] continues <br>
<span style="font-size:85%;color:red">[[Contraindication|<span style="color:red">Contraindications:</span>]] [[Hypersensitivity|<span style="color:red">hypersensitivity</span>]] to [[Ibutilide|<span style="color:red">ibutilide</span>]] or any component of the formulation, [[QT interval|<span style="color:red">QTc</span>]] >440 msec</span>
<span style="font-size:85%;color:red">[[Contraindication|<span style="color:red">Contraindications:</span>]] [[Hypersensitivity|<span style="color:red">hypersensitivity</span>]] to [[Ibutilide|<span style="color:red">ibutilide</span>]] or any component of the formulation, [[QT interval|<span style="color:red">QTc</span>]] >440 msec</span>
|-
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=left |[[Flecainide]]
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=left |  50 mg every 12 hours
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=left |❑ Increase 50mg BID every four days until efficacy is achieved <br>
❑ Maximum dose recommended for [[supraventricular tachycardia]] is 300 mg/day <br>
<span style="font-size:85%;color:red">[[Contraindication|<span style="color:red">Contraindications:</span>]] pre-existing [[Second degree AV block|<span style="color:red">second degree AV block</span>]] or [[Third degree AV block|<span style="color:red">third degree AV block</span>]] , [[Right bundle branch block|<span style="color:red">right bundle branch block</span>]] associated with a left hemiblock unless a [[Artificial pacemaker|<span style="color:red">pacemaker</span>]] is present, [[Shock|<span style="color:red">cardiogenic shock</span>]], [[Hypersensitivity|<span style="color:red">hypersensitivity</span>]] to the drug</span>
|}
|}



Revision as of 06:01, 16 September 2020

Wolff-Parkinson-White syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Wolff-Parkinson-White syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Approach

History and Symptoms

Electrocardiogram

EKG Examples

Other Diagnostic Studies

Treatment

Risk Stratification

Cardioversion

Medical Therapy

Catheter Ablation

Prophylaxis

Consensus Statement

Case Studies

Case #1

Wolff-Parkinson-White syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Wolff-Parkinson-White syndrome medical therapy

CDC onWolff-Parkinson-White syndrome medical therapy

Wolff-Parkinson-White syndrome medical therapy in the news

Blogs on Wolff-Parkinson-White syndrome medical therapy

Directions to Hospitals Treating Deep vein thrombosis

Risk calculators and risk factors for Wolff-Parkinson-White syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Rim Halaby, M.D. [3]

Overview

Wolff-Parkinson-White (WPW) syndrome patients who are hemodynamically unstable, as reflected by the presence of hypotension, cold extremities, mottling or peripheral cyanosis, or those who present with ischemic chest pain or decompensated heart failure should urgently undergo direct current cardioversion.[1] The medical therapy of hemodynamically stable patients with WPW syndrome depends on the type of the tachycardia. When the ECG findings suggest orthodromic AVRT, the patient should be managed similarly to patients with supreventricular tachycardia followed by the sequential administration of adenosine, verapamil and procainamide in case of failure to improve. Among patients with antidromic AVRT, AV nodal blocking agents should be avoided and patients should be treated with either procainamide, ibutilide or flecainide.[2] In case of WPW syndrome with atrial fibrillation in hemodynamically stable patients, procainamide, ibutilide or flecainide can be administered.[3] The long term treatment of patients with WPW syndrome depends on the presence or absence of symptoms and their severity. Patients who have poorly tolerated symptomatic WPW syndrome should undergo [[catheter ablation.[2]

Acute Treatment

Atrioventricular Reentrant Tachycardia (AVRT)

  • AVRT is one of the type of tachycardia that can occur in patients with WPW pattern. AVRT can be either orthodromic or antidromic, and the distinction between the two types is important because it dictates the choice of treatment.

Hemodynamically Unstable Patients

  • WPW syndrome patients with AVRT who are hemodynamically unstable, as reflected by the presence of hypotension, cold extremities, mottling or peripheral cyanosis, or those who present with ischemic chest pain or decompensated heart failure should urgently undergo direct current cardioversion. The shocks should be delivered as follows:
    • Narrow regular rhythm: synchronized electrical cardioversion, 50-100 Joules
    • Narrow irregular rhythm: synchronized electrical cardioversion, 120-200 Joules biphasic or 200 Joules monophasic
    • Wide regular rhythm: synchronized electrical cardioversion, 100 Joules
    • Wide irregular rhythm: unsynchronized electrical cardioversion, 200-360 Joules monophasic, or 100-200 Joules biphasic[1]

Orthodromic [[AVRT] in Hemodynamically Stable Patients

The sequence of therapeutic decisions is summarized below.[4]

Recommendations for acute treatment of orthodromic AVRT
Vagal maneuver (Class I, Level of Evidence B):

Carotid sinus massage for 5-10 seconds in the absent of bruit
Valsalva maneuver for 10-30 seconds by bearing down against closed glottis,more successful technique
❑ Applying ice-cold wet towel to the face

Adenosin(Class I, Level of Evidence B) :

❑ Effective in conversion of AVRT in 90-95% patients
❑ Episode of AVRT may be induced again by PAC or PVC after termination of tachyarrhythmia by adenosin
AF may be induced by adenosin, rapidly passing through accessory pathway Contraindications: asthma, second degree AV block or third degree AV block unless a pacemaker is present

Synchronized cardioversion : (Class I, Level of Evidence B)
❑ Highly effective in termination of AVRT

❑ In unstable hemodynamic or stable hemodynamic and ineffectiveness of vagal maneuver or adenosin is recommended
❑ Avoidance of complications associated antiarrhythmic drugs
❑ In the presence of PVC or PAC just after cardioversion, antiarrhythmic drugs is recommended for prevention of restarting AVRT
❑ In the presence of hemodynamically unstable and preexcited AF, synchronized cardioversion is recommended

Ibutilide or intravenous procainamide:(Class I, Level of Evidence C)

❑ effective in hemodynamic stable and preexcited AF by slowing conduction over the accessory pathway
Contraindications: Compromised left ventricular function

Intravenous diltiazem,verapamil ,beta blockers : (Class 2a, Level of Evidence B-C)

❑ Effective for acute treatment of orthodromic AVRT with out pre-excitation on resting ECG during sinus rhythm(LOR=B)
❑ Intravenous diltiazem or verapamil effectively terminate 90% to 95% of AVRT with out pre-excitation on their resting sinus-rhythm ECG
❑ Hypotension may occur in 3% patients receiving Intravenous diltiazem or verapamil
❑ Intravenous beta blocker are effective for terminating AVRT with low risk of associated complications(LOR=C)

Intravenous betablockers,diltiazem,verapamil (Class 2b, Level of Evidence B):

❑ Acute termination of orthodromic AVRT with pre-excitation on resting ECG with out response to other treatment
❑ Complication is enhancing conduction over the accessory pathway if the AVRT converts to AF during administration of the medication

Intravenous digoxin,intravenous amiodarone,intravenous or oral beta blockers,diltiazem,verapamil : (Class 3, Harm, Level of Evidence B)

❑ Harmful in acute termination of peexcitated AF due to increased risk of ventricular fibrillation by these mechanism:
❑ Increased conduction over the accessory pathway and slowing or blocking conduction over AV node
❑ Deceased refractory period of accessory pathway by digoxin
❑ Increased cathecolamin due to drug induced hypotension such as amiodarone, beta blocker, verapamil, diltiazem

Antidromic AVRT in Hemodynamically Stable Patients

Treatment of Antidromic AVRT in Hemodynamically Stable Patients
Medication Dosage Notes
Procainamide 100 mg infusion diluted to 100mg/ml at a rate of 25-50 mg/min every 5 minutes ❑ Give until the arrhythmia is suppressed or until 500 mg has been administered

❑ Wait 10 minutes or longer to administer new dosage
Contraindications: third degree AV block, lupus erythematosus, idiosyncratic hypersensitivity, torsades de pointes

Ibutilide 1 mg IV infusion over 10 minutes ❑ Repeat the dosage if the tachycardia continues

Contraindications: hypersensitivity to ibutilide or any component of the formulation, QTc >440 msec

Atrial Fibrillation

Hemodynamically Unstable Patients

In hemodynamically unstable patients, urgent direct current cardioversion should be performed.[1]

Hemodynamically Stable Patients

Long Term Treatment

The long term management of patients with WPW syndrome depends on the presence or absence of syndrome. Among symptomatic patients, the tolerability of the symptoms guides the choice of the long term treatment.[2]

Asymptomatic Patients

Symptomatic Patients

Contraindicated medications

WPW SYNDROME is considered an absolute contraindication to the use of the following medications:

References

  1. 1.0 1.1 1.2 "Part 8: Adult Advanced Cardiovascular Life Support". Retrieved 3 April 2014.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 "ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias—Executive Summary". Retrieved 15 August 2013.
  3. 3.0 3.1 American College of Cardiology Foundation. American Heart Association. European Society of Cardiology. Heart Rhythm Society. Wann LS, Curtis AB; et al. (2013). "Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines". Circulation. 127 (18): 1916–26. doi:10.1161/CIR.0b013e318290826d. PMID 23545139.
  4. 4.0 4.1 Page, Richard L.; Joglar, José A.; Caldwell, Mary A.; Calkins, Hugh; Conti, Jamie B.; Deal, Barbara J.; Estes III, N.A. Mark; Field, Michael E.; Goldberger, Zachary D.; Hammill, Stephen C.; Indik, Julia H.; Lindsay, Bruce D.; Olshansky, Brian; Russo, Andrea M.; Shen, Win-Kuang; Tracy, Cynthia M.; Al-Khatib, Sana M. (2016). "2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia". Heart Rhythm. 13 (4): e136–e221. doi:10.1016/j.hrthm.2015.09.019. ISSN 1547-5271.

Template:WH Template:WS